Top-News
Quelle: - © zozzzzo / iStock / Getty Images Plus / Getty Images:
Boston Scientific announces results for fourth quarter and full year 2024
MARLBOROUGH, Mass., Feb. 5, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $4.561 billion during the fourth quarter of 2024, growing 22.4 percent on a reported basis, 23.1 percent on an operational1 basis and 19.5 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $566 million or $0.38 per share (EPS), compared to $504 million or $0.34 per share a year ago and achieved adjusted3 EPS of $0.70 for the period, compared to $0.55 a year ago.
For the full year 2024, the company generated net sales of $16.747 billion, growing 17.6 percent on a reported basis, 18.5 percent on an operational1 basis and 16.4 percent on an organic2 basis. The company reported GAAP net income attributable to Boston Scientific common stockholders of $1.853 billion or $1.25 per share, compared to $1.570 billion or $1.07 per share a year ago, and delivered full year adjusted3 EPS of $2.51, compared to $2.05 a year ago.
"2024 was one of the best years in the history of Boston Scientific, fueled by our innovative portfolio, the launch of our FARAPULSE™ Pulsed Field Ablation System as well as significant clinical achievements and commercial excellence across businesses and regions," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We have a strong foundation for growth, and I am incredibly grateful for our talented global team and the opportunity to continue transforming the lives of millions of patients around the world."
Fourth quarter financial results and recent developments:
- Reported net sales of $4.561 billion, representing an increase of 22.4 percent on a reported basis, compared to the company's guidance range of 16.5 to 18.5 percent; 23.1 percent on an operational basis; and 19.5 percent on an organic basis, compared to the company's guidance range of 14 to 16 percent, all compared to the prior year period.
- Reported GAAP net income attributable to Boston Scientific common stockholders of $0.38 per share, compared to the company's guidance range of $0.41 to $0.43 per share, and achieved adjusted EPS of $0.70 per share, compared to the guidance range of $0.64 to $0.66 per share.
- Achieved the following net sales growth in each reportable segment, compared to the prior year period:
- MedSurg: 12.4 percent reported, 13.0 percent operational and 7.0 percent organic
- Cardiovascular: 28.8 percent reported, 29.5 percent operational and 27.4 percent organic
- Achieved the following net sales growth in each region, compared to the prior year period:
- United States (U.S.): 30.7 percent reported and operational
- Europe, Middle East and Africa (EMEA): 10.8 percent reported and 11.6 percent operational
- Asia-Pacific (APAC): 11.1 percent reported and 12.4 percent operational
- Latin America and Canada (LACA): 4.6 percent reported and 12.6 percent operational
- Emerging Markets4: 12.4 percent reported and 15.2 percent operational
- Presented positive 36-month primary endpoint findings from the OPTION clinical trial at the American Heart Association Scientific Sessions demonstrating superior bleeding risk reduction and similar efficacy with the WATCHMAN FLX™ Left Atrial Appendage Closure Device compared to oral anticoagulation in high-risk patients with atrial fibrillation (AF) post ablation, followed by a late-breaking sub-analysis at AF Symposium 2025 reaffirming positive outcomes with the device in both concomitant and sequential procedures.
- Presented positive 12-month primary endpoint findings from phase one of the ADVANTAGE AF clinical trial at AF Symposium 2025 that achieved the safety and effectiveness endpoints for the treatment of patients with persistent AF with the FARAPULSE™ Pulsed Field Ablation System.
- Received U.S. Centers for Medicare & Medicaid Services approval of a new transitional pass-through payment for the AGENT™ Drug-Coated Balloon effective Jan. 1, 2025, which offers facilities additional reimbursement for outpatient procedures.
- Received both U.S. Food and Drug Administration (FDA) approval and CE mark for the Vercise™ Cartesia™ X and HX Directional Leads, the first and only 16-contact directional leads designed for more precise targeting for enhanced clinical outcomes using the Vercise Genus™ Deep Brain Stimulation System.
- Completed the acquisition of Axonics, Inc., an innovative medical technology company focused on the development and commercialization of differentiated devices for the treatment of urinary and bowel dysfunction.
- Announced and completed the acquisition of Cortex, Inc., a privately held medical technology company focused on the development of a diagnostic mapping solution which aims to identify triggers and drivers outside of the pulmonary veins that are foundational to AF.
- Announced agreements to acquire the following companies, subject to customary closing conditions:
- Bolt Medical, Inc., a developer of an intravascular lithotripsy advanced laser-based platform for the treatment of coronary and peripheral artery disease which is pending U.S. FDA approval.
- Intera Oncology® Inc., a medical device company that provides the Intera 3000 Hepatic Artery Infusion Pump and floxuridine, a chemotherapy drug.
| 1 Operational net sales growth excludes the impact of foreign currency fluctuations. |
| 2 Organic net sales growth excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. |
| 3 Adjusted EPS excludes the impacts of certain charges (credits) which may include amortization expense, goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), investment portfolio net losses (gains) and impairments, restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), European Union Medical Device Regulation (EU MDR) implementation costs, debt extinguishment net charges, deferred tax expenses (benefits) and certain discrete tax items. |
| 4 Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2023, modified our list to include all countries except the United States, Western and Central Europe, Japan, Australia, New Zealand and Canada. |
Fourth quarter net sales by business and region:
| | | | | | Increase/(Decrease) | ||||||||
| | | Three Months Ended | | Reported | | Impact of | | Operational | | Impact of | | Organic | |
| (in millions) | 2024 | 2023 | | | | | | ||||||
| | Endoscopy | $ 690 | $ 645 | | 7.0 % | | 0.6 % | | 7.6 % | | (0.7) % | | 7.0 % |
| | Urology | 630 | 527 | | 19.5 % | | 0.5 % | | 20.1 % | | (12.2) % | | 7.9 % |
| | Neuromodulation | 299 | 269 | | 11.4 % | | 0.5 % | | 11.9 % | | (6.4) % | | 5.5 % |
| | MedSurg | 1,619 | 1,441 | | 12.4 % | | 0.6 % | | 13.0 % | | (6.0) % | | 7.0 % |
| | Cardiology | 2,297 | 1,751 | | 31.1 % | | 0.8 % | | 31.9 % | | — % | | 31.9 % |
| | Peripheral Interventions | 645 | 533 | | 21.0 % | | 0.8 % | | 21.7 % | | (9.2) % | | 12.5 % |
| | Cardiovascular | 2,942 | 2,285 | | 28.8 % | | 0.8 % | | 29.5 % | | (2.2) % | | 27.4 % |
| Net Sales | $ 4,561 | $ 3,725 | | 22.4 % | | 0.7 % | | 23.1 % | | (3.6) % | | 19.5 % | |
| | | | | | |||||||||
| | | | | | Increase/(Decrease) | ||||
| | | Three Months Ended | | Reported | | Impact of | | Operational | |
| (in millions) | 2024 | 2023 | | | | ||||
| | U.S. | $ 2,893 | $ 2,213 | | 30.7 % | | — % | | 30.7 % |
| | EMEA | 830 | 749 | | 10.8 % | | 0.9 % | | 11.6 % |
| | APAC | 684 | 616 | | 11.1 % | | 1.2 % | | 12.4 % |
| | LACA | 155 | 148 | | 4.6 % | | 8.0 % | | 12.6 % |
| | Net Sales | $ 4,561 | $ 3,725 | | 22.4 % | | 0.7 % | | 23.1 % |
| | | | | | | | | | |
| | Emerging Markets4 | $ 668 | $ 595 | | 12.4 % | | 2.8 % | | 15.2 % |
| | | | | | | | | | |
| |
Amounts may not foot due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | ||||||||
| | | ||||||||
| | Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions/divestitures are not prepared in | ||||||||
Full year net sales by business and region:
| | | | | | Increase/(Decrease) | ||||||||
| | | Year Ended December 31, | | Reported | | Impact of | | Operational | | Impact of | | Organic | |
| (in millions) | 2024 | 2023 | | | | | | ||||||
| | Endoscopy | $ 2,687 | $ 2,482 | | 8.3 % | | 0.6 % | | 8.9 % | | (1.0) % | | 8.0 % |
| | Urology | 2,200 | 1,964 | | 12.0 % | | 0.5 % | | 12.5 % | | (3.3) % | | 9.3 % |
| | Neuromodulation | 1,106 | 976 | | 13.3 % | | 0.4 % | | 13.7 % | | (11.0) % | | 2.7 % |
| | MedSurg | 5,993 | 5,422 | | 10.5 % | | 0.6 % | | 11.1 % | | (3.6) % | | 7.5 % |
| | Cardiology | 8,344 | 6,709 | | 24.4 % | | 1.0 % | | 25.4 % | | — % | | 25.4 % |
| | Peripheral Interventions | 2,410 | 2,110 | | 14.2 % | | 1.2 % | | 15.5 % | | (4.6) % | | 10.9 % |
| | Cardiovascular | 10,755 | 8,819 | | 22.0 % | | 1.1 % | | 23.0 % | | (1.1) % | | 21.9 % |
| Net Sales | $ 16,747 | $ 14,240 | | 17.6 % | | 0.9 % | | 18.5 % | | (2.1) % | | 16.4 % | |
| | | | | | | | | | | | | | |
| | | | | | Increase/(Decrease) | ||||
| | | Year Ended December 31, | | Reported | | Impact of | | Operational | |
| (in millions) | 2024 | 2023 | | | | ||||
| | U.S. | $ 10,210 | $ 8,425 | | 21.2 % | | — % | | 21.2 % |
| | EMEA | 3,228 | 2,856 | | 13.0 % | | 0.8 % | | 13.8 % |
| | APAC | 2,686 | 2,400 | | 11.9 % | | 3.7 % | | 15.7 % |
| | LACA | 624 | 560 | | 11.4 % | | 2.6 % | | 14.1 % |
| | Net Sales | $ 16,747 | $ 14,240 | | 17.6 % | | 0.9 % | | 18.5 % |
| | | | | | | | | | |
| | Emerging Markets4 | $ 2,680 | $ 2,310 | | 16.1 % | | 3.6 % | | 19.6 % |
| | | | | | | | | | |
| | Amounts may not foot due to rounding. Growth rates are based on actual, non-rounded amounts and may not recalculate precisely. | ||||||||
| | | ||||||||
| | Net sales growth rates that exclude the impact of foreign currency fluctuations and/or the impact of acquisitions/divestitures are not prepared in | ||||||||
Guidance for Full Year and First Quarter 2025
The company estimates net sales growth for the full year 2025, versus the prior year period, to be in a range of approximately 12.5 to 14.5 percent on a reported basis, and approximately 10 to 12 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.86 to $1.93 and estimates adjusted EPS, excluding certain charges (credits), of $2.80 to $2.87.
The company estimates net sales growth for the first quarter of 2025, versus the prior year period, to be in a range of approximately 17 to 19 percent on a reported basis, and approximately 14 to 16 percent on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.43 to $0.45 and estimates adjusted EPS, excluding certain charges (credits), of $0.66 to $0.68.
Conference Call Information
Boston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. ET. The company will webcast the call to interested parties through its website: investors.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our expected net sales; reported, operational and organic revenue growth rates; reported and adjusted EPS for the first quarter and full year 2025; our financial performance; acquisitions; clinical trials; our business plans and product performance; and new and anticipated product approvals and launches. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
Note: Amounts reported in millions within this press release are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying unrounded amounts.
Use of Non-GAAP Financial Information
A reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non-GAAP financial measures, is included in the exhibits attached to this press release.
| CONTACT: | | | | |
| Media: | Chanel Hastings | | Investors: | Jonathan Monson |
| | 508-382-0288 (office) | | | 508-683-5450 (office) |
| | Media Relations | | | Investor Relations |
| | Boston Scientific Corporation | | | Boston Scientific Corporation |
| | | |
| BOSTON SCIENTIFIC CORPORATION | |||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||
| (Unaudited) | |||||
| | |||||
| | Three Months Ended December 31, | | Year Ended December 31, | ||
| in millions, except per share data | 2024 | 2023 | | 2024 | 2023 |
| | | | | | |
| | | | | | |
| Net sales | $ 4,561 | $ 3,725 | | $ 16,747 | $ 14,240 |
| Cost of products sold | 1,466 | 1,146 | | 5,257 | 4,345 |
| Gross profit | 3,095 | 2,579 | | 11,490 | 9,896 |
| | | | | | |
| Operating expenses: | | | | | |
| Selling, general and administrative expenses | 1,612 | 1,379 | | 5,984 | 5,190 |
| Research and development expenses | 460 | 363 | | 1,615 | 1,414 |
| Royalty expense | 10 | 12 | | 33 | 46 |
| Amortization expense | 225 | 208 | | 856 | 828 |
| Intangible asset impairment charges | 111 | — | | 386 | 58 |
| Contingent consideration net expense (benefit) | (1) | 14 | | (5) | 58 |
| Restructuring net charges (credits) | 4 | 19 | | 16 | 69 |
| Litigation-related net charges (credits) | — | — | | — | (111) |
| | 2,420 | 1,995 | | 8,887 | 7,553 |
| Operating income (loss) | 675 | 584 | | 2,603 | 2,343 |
| | | | | | |
| Other income (expense): | | | | | |
| Interest expense | (80) | (65) | | (305) | (265) |
| Other, net | (10) | (14) | | (16) | (93) |
| Income (loss) before income taxes | 585 | 505 | | 2,282 | 1,985 |
| Income tax expense (benefit) | 23 | 1 | | 436 | 393 |
| Net income (loss) | $ 562 | $ 504 | | $ 1,846 | $ 1,592 |
| Preferred stock dividends | — | — | | — | (23) |
| Net income (loss) attributable to noncontrolling interests | (4) | (0) | | (8) | (1) |
| Net income (loss) attributable to Boston Scientific | $ 566 | $ 504 | | $ 1,853 | $ 1,570 |
| | | | | | |
| Net income (loss) per common share - basic | $ 0.38 | $ 0.34 | | $ 1.26 | $ 1.08 |
| Net income (loss) per common share - diluted | $ 0.38 | $ 0.34 | | $ 1.25 | $ 1.07 |
| | | | | | |
| Weighted-average shares outstanding | | | | | |
| Basic | 1,474.2 | 1,465.3 | | 1,471.5 | 1,453.0 |
| Diluted | 1,490.2 | 1,476.9 | | 1,485.9 | 1,463.5 |
| | | | | | |
| Amounts may not foot due to rounding. | | | | | |
| BOSTON SCIENTIFIC CORPORATION | |||||||||
| NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS | |||||||||
| (Unaudited) | |||||||||
| | |||||||||
| | Three Months Ended December 31, 2024 | ||||||||
| in millions, except per share data | Gross | Operating | Operating | Other | Income | Net | Net Income | Net Income | Impact |
| Reported | $ 3,095 | $ 2,420 | $ 675 | $ (90) | $ 585 | $ 562 | $ (4) | $ 566 | $ 0.38 |
| Non-GAAP adjustments: | | | | | | | | | |
| Amortization expense | — | (225) | 225 | — | 225 | 198 | 2 | 196 | 0.13 |
| Intangible asset impairment | — | (111) | 111 | — | 111 | 96 | — | 96 | 0.06 |
| Acquisition/divestiture-related | 63 | (84) | 147 | 0 | 147 | 61 | — | 61 | 0.04 |
| Restructuring and restructuring- | 56 | (24) | 80 | — | 80 | 70 | — | 70 | 0.05 |
| Litigation-related net charges | — | — | — | — | — | (0) | — | (0) | (0.00) |
| Investment portfolio net losses | — | — | — | 2 | 2 | 1 | — | 1 | 0.00 |
| EU MDR implementation costs | 9 | (5) | 13 | — | 13 | 12 | — | 12 | 0.01 |
| Deferred tax expenses (benefits) | — | — | — | — | — | 45 | — | 45 | 0.03 |
| Discrete tax items | — | — | — | — | — | (4) | — | (4) | (0.00) |
| Adjusted | $ 3,222 | $ 1,971 | $ 1,251 | $ (87) | $ 1,164 | $ 1,041 | $ (1) | $ 1,043 | $ 0.70 |
| | | | | | | | | | |
| | Three Months Ended December 31, 2023 | ||||||||
| in millions, except per share data | Gross | Operating | Operating | Other | Income | Net | Net Income | Net Income | Impact |
| Reported | $ 2,579 | $ 1,995 | $ 584 | $ (79) | $ 505 | $ 504 | $ (0) | $ 504 | $ 0.34 |
| Non-GAAP adjustments: | | | | | | | | | |
| Amortization expense | — | (208) | 208 | — | 208 | 178 | 2 | 176 | 0.12 |
| Acquisition/divestiture-related | 9 | (120) | 129 | (0) | 129 | 54 | — | 54 | 0.04 |
| Restructuring and restructuring- | 22 | (30) | 52 | — | 52 | 43 | — | 43 | 0.03 |
| Litigation-related net charges | — | — | — | — | — | (1) | — | (1) | (0.00) |
| Investment portfolio net losses | — | — | — | (0) | (0) | 2 | — | 2 | 0.00 |
| EU MDR implementation costs | 11 | (5) | 16 | — | 16 | 14 | — | 14 | 0.01 |
| Deferred tax expenses (benefits) | — | — | — | — | — | 44 | — | 44 | 0.03 |
| Discrete tax items | — | — | — | — | — | (18) | — | (18) | (0.01) |
| Adjusted | $ 2,621 | $ 1,631 | $ 990 | $ (79) | $ 911 | $ 819 | $ 2 | $ 817 | $ 0.55 |
| | | | | | | | | | |
| | | | | | | | | | |
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. | |||||||||
| | |||||||||
| Amounts may not foot due to rounding. | |||||||||
| BOSTON SCIENTIFIC CORPORATION | ||||||||||
| NON-GAAP NET INCOME AND NET INCOME PER SHARE RECONCILIATIONS | ||||||||||
| (Unaudited) | ||||||||||
| | ||||||||||
| | Year Ended December 31, 2024 | |||||||||
| in millions, except per share data | Gross | Operating | Operating | Other | Income | Net | Preferred | Net Income | Net Income | Impact |
| Reported | $ 11,490 | $ 8,887 | $ 2,603 | $ (321) | $ 2,282 | $ 1,846 | $ — | $ (8) | $ 1,853 | $ 1.25 |
| Non-GAAP adjustments: | | | | | | | | | | |
| Amortization expense | — | (856) | 856 | — | 856 | 743 | — | 9 | 734 | 0.49 |
| Intangible asset | — | (386) | 386 | — | 386 | 339 | — | — | 339 | 0.23 |
| Acquisition/divestiture- | 111 | (291) | 402 | 1 | 403 | 375 | — | — | 375 | 0.25 |
| Restructuring and | 139 | (90) | 229 | — | 229 | 199 | — | — | 199 | 0.13 |
| Litigation-related net | — | — | — | — | — | (0) | — | — | (0) | (0.00) |
| Investment portfolio net | — | — | — | 20 | 20 | 19 | — | — | 19 | 0.01 |
| EU MDR implementation | 35 | (17) | 52 | — | 52 | 45 | — | — | 45 | 0.03 |
| Deferred tax expenses | — | — | — | — | — | 165 | — | — | 165 | 0.11 |
| Discrete tax items | — | — | — | — | — | (4) | — | — | (4) | (0.00) |
| Adjusted | $ 11,776 | $ 7,246 | $ 4,529 | $ (301) | $ 4,229 | $ 3,726 | $ — | $ 1 | $ 3,725 | $ 2.51 |
| | | | | | | | | | | |
| | Year Ended December 31, 2023 | |||||||||
| in millions, except per share data | Gross | Operating | Operating | Other | Income | Net | Preferred | Net Income | Net Income | Impact |
| Reported | $ 9,896 | $ 7,553 | $ 2,343 | $ (358) | $ 1,985 | $ 1,592 | $ (23) | $ (1) | $ 1,570 | $ 1.07 |
| Non-GAAP adjustments: | | | | | | | | | | |
| Amortization expense | — | (828) | 828 | — | 828 | 713 | — | 4 | 709 | 0.48 |
| Intangible asset | — | (58) | 58 | — | 58 | 54 | — | — | 54 | 0.04 |
| Acquisition/divestiture- | 53 | (314) | 367 | 6 | 373 | 352 | — | — | 352 | 0.24 |
| Restructuring and | 77 | (107) | 185 | — | 185 | 156 | — | — | 156 | 0.11 |
| Litigation-related net | — | 111 | (111) | — | (111) | (88) | — | — | (88) | (0.06) |
| Investment portfolio net | — | — | — | 21 | 21 | 24 | — | — | 24 | 0.02 |
| EU MDR implementation | 47 | (21) | 69 | — | 69 | 59 | — | — | 59 | 0.04 |
| Deferred tax expenses | — | — | — | — | — | 155 | — | — | 155 | 0.11 |
| Discrete tax items | — | — | — | — | — | 8 | — | — | 8 | 0.01 |
| Adjusted | $ 10,073 | $ 6,335 | $ 3,738 | $ (331) | $ 3,407 | $ 3,025 | $ (23) | $ 4 | $ 2,999 | $ 2.05 |
| | | | | | | | | | | |
| (1) For the year ended December 31, 2023, the effect of assuming the conversion of Mandatory Convertible Preferred Stock, Series A MCPS into shares | ||||||||||
| | ||||||||||
| An explanation of the company's use of these non-GAAP financial measures is provided at the end of this document. | ||||||||||
| | ||||||||||
| Amounts may not foot due to rounding. | ||||||||||
BOSTON SCIENTIFIC CORPORATION
Q1 and FY 2025 GUIDANCE RECONCILIATIONS
(Unaudited)
Net Sales
| | Q1 2025 Estimate | | Full Year 2025 Estimate | ||
| | (Low) | (High) | | (Low) | (High) |
| Reported growth | 17.0 % | 19.0 % | | 12.5 % | 14.5 % |
| Impact of foreign currency fluctuations | 1.0 % | 1.0 % | | 1.0 % | 1.0 % |
| Operational growth | 18.0 % | 20.0 % | | 13.5 % | 15.5 % |
| Impact of acquisitions/divestitures | (4.0) % | (4.0) % | | (3.5) % | (3.5) % |
| Organic growth | 14.0 % | 16.0 % | | 10.0 % | 12.0 % |
| | | | | | |
Earnings per Share
| | Q1 2025 Estimate | | Full Year 2025 Estimate | ||
| | (Low) | (High) | | (Low) | (High) |
| GAAP results | $ 0.43 | $ 0.45 | | $ 1.86 | $ 1.93 |
| | | | | | |
| Amortization expense | 0.14 | 0.14 | | 0.55 | 0.55 |
| Acquisition/divestiture-related net charges (credits) | 0.03 | 0.03 | | 0.10 | 0.10 |
| Restructuring and restructuring-related net charges (credits) | 0.03 | 0.03 | | 0.11 | 0.11 |
| Other adjustments | 0.04 Für dich aus unserer Redaktion zusammengestelltDein Kommentar zum Artikel im Forum Jetzt anmelden und diskutieren
Registrieren
Login
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Weitere Artikel des AutorsThemen im Trend | ||||